Current through Register Vol. 30, No. 38, September 20, 2024
A. A first response agency shall, either
personally or through a representative, submit a report to the Department, in a
Department-provided format and within five business days after an encounter
with an individual with a suspected opioid overdose, that includes:
1. The following information about the first
response agency:
a. Name;
b. Street address, city, county, and zip
code;
c. Whether the first response
agency reporting is:
i. An ambulance
service,
ii. An emergency medical
services provider, or
iii. A law
enforcement agency; and
d. If applicable, the certificate number
issued by the Department to the ambulance service;
2. The name, title, telephone number, and
email address of a point of contact for the first response agency required to
report;
3. The following
information about the location at which the first response agency encountered
the individual:
a. Street address or, if the
location at which the first response agency encountered the individual does not
have a street address, another indicator of the location at which the encounter
occurred;
b. City, if
applicable;
c. County;
d. State; and
e. Zip code;
4. If applicable, the date and time the first
response agency was dispatched to the location specified according to
subsection (A)(3);
5. The following
information, as known, about the individual with a suspected opioid overdose or
who died of a suspected opioid overdose:
a.
Name,
b. Date of birth,
c. Age in years,
d. Gender,
e. Race and ethnicity, and
f. Reason for suspecting that the individual
had an opioid overdose;
6. Whether naloxone or another opioid
antagonist designated according to A.R.S. §
36-2228
was administered to the individual before the first response agency encountered
the individual and, if so:
a. The number of
doses of naloxone or other opioid antagonist administered to the individual;
and
b. As applicable, that the
naloxone or other opioid antagonist was administered to the individual by:
i. Another individual; or
ii. Another first response agency and, if so
the type of first response agency that administered the naloxone or other
opi-oid antagonist to the individual;
7. Whether naloxone or another opioid
antagonist designated according to A.R.S. §
36-2228
was administered to the individual by the first response agency and, if so, the
number of doses of naloxone or other opioid antagonist administered to the
individual;
8. Whether the
disposition of the individual was that the individual:
a. Survived the suspected opioid overdose;
or
b. Was pronounced dead:
i. At the location specified according to
subsection (A)(3), or
ii. After
leaving the location specified according to subsection (A)(3);
9. If the individual
was transported by a first response agency:
a.
The type of first response agency that transported the individual;
and
b. Whether the individual was
transported to:
i. A hospital and, if so, the
name of the hospital to which the individual was transported;
ii. Another class of health care institution
and, if so, the name of the health care institution to which the individual was
transported; or
iii. A
correctional facility and, if so, the name of the correctional facility to
which the individual was transported; and
10. The date of the report.
B. The following are not required
to submit a report under this Article:
1. An
administrator of a health care institution licensed under 9 A.A.C. 10, for an
opioid overdose resulting from the administration of the opioid to a patient in
the health care institution if the opioid overdose is addressed through the
health care institution's quality management program; or
2. A pharmacist for naloxone or another
opioid antagonist that is dispensed in connection with a surgical procedure, as
defined in A.A.C.
R9-10-101, or other
invasive procedure performed in a health care institution.
C. Except as prohibited by Title 42 Code of
Federal Regulations, Chapter I, Subchapter A, Part 2 or as specified in
subsection (B), a health professional or the administrator of a health care
institution licensed under 9 A.A.C. 10 shall, either personally or through a
representative, submit a report to the Department, in a Department-provided
format and within five business days after an encounter with an individual with
a suspected opioid overdose, that includes:
1.
The name, street address, city, county, zip code, and telephone number of the
health professional or health care institution;
2. If different from the person in subsection
(C)(1), the name, title, telephone number, and email address of the individual
reporting on behalf of the person in subsection (C)(1);
3. The following information about the
individual with a suspected opioid overdose:
a. The individual's name;
b. The individual's street address, city,
county, state, and zip code;
c. The
individual's date of birth;
d. The
individual's gender;
e. The
individual's race and ethnicity;
f.
Whether the individual is pregnant and, if so, the expected date of
delivery;
g. If applicable, the
name of the individual's guardian; and
h. Whether naloxone or another opioid
antagonist designated according to A.R.S. §
36-2228
was administered to the individual before the health professional or health
care institution encountered the individual and, if so:
i. The type of first response agency that
administered the naloxone or other opioid antagonist to the individual, or
ii. That the naloxone or other
opioid antagonist was administered to the individual by another
individual;
4. The following information about the
diagnosis of opioid overdose:
a. The reason
for suspecting that the individual had an opioid overdose;
b. The date of the suspected opioid
overdose;
c. The date of diagnosis;
and
d. If the diagnosis was
confirmed through one or more tests performed by a clinical laboratory, for
each test:
i. The name, address, and
telephone number of the clinical laboratory;
ii. The date a specimen was collected from
the individual;
iii. The type of
specimen collected;
iv. The type
of laboratory test performed; and
v. The laboratory test result and date of the
result;
5.
The following information about the suspected opioid overdose:
a. Whether the opioid overdose appeared to be
intentional or unintentional;
b.
The location where the opioid overdose took place;
c. Whether the individual was alone at the
time of the opioid overdose;
d.
Whether the individual was transported to the health professional or health
care institution by a first response agency and, if so, the type of first
response agency that transported the individual;
e. The specific opioid that appeared to be
responsible for the opioid overdose; and
f. If known, whether:
i. The individual was prescribed an opioid
within the 90 calendar days before the date of the suspected opioid overdose;
ii. The individual had been
referred to receive behavioral health services, as defined in A.R.S. §
36-401;
or
iii. The opioid overdose was
the first time the individual had had an opioid overdose and, if not, the
number of previous opioid overdoses the individual was known to have
had;
6.
Whether the individual with the suspected opioid overdose:
a. Survived the suspected opioid overdose
and:
i. Was admitted to the health care
institution;
ii. Was transferred to
another health care institution and, if so, the name of the health care
institution;
iii. Was discharged to
a law enforcement agency or correctional facility and, if so, the name of the
law enforcement agency or correctional facility;
iv. Was discharged to home; or
v. Left the health care institution against
medical advice; or
b.
Died and, if so, the date of death; and
7. The date of the report.
D. Except as prohibited by Title
42 Code of Federal Regulations, Chapter I, Subchapter A, Part 2, a health
professional or the administrator of a health care institution licensed under 9
A.A.C. 10 shall, either personally or through a representative, submit a report
to the Department, in a Department-provided format and within five business
days after an encounter with an individual with suspected neonatal abstinence
syndrome, that includes:
1. The name, street
address, city, county, zip code, and telephone number of the health
professional or health care institution;
2. If different from the person in subsection
(D)(1), the name, title, telephone number, and email address of the individual
reporting on behalf of the person in subsection (D)(1);
3. The following information about the
individual with suspected neonatal abstinence syndrome:
a. The individual's name;
b. The individual's date of birth;
c. The individual's gender;
d. The individual's race and
ethnicity;
e. The name of the
individual's mother; and
f. If not
the individual's mother, the name of the individual's guardian;
4. The following information about
a diagnosis of neonatal abstinence syndrome:
a. The reason for suspecting that the
individual has neonatal abstinence syndrome;
b. The date of the onset of signs of neonatal
abstinence syndrome;
c. The date of
diagnosis;
d. If the diagnosis was
confirmed through one or more tests performed by a clinical laboratory, for
each test:
i. The name, address, and
telephone number of the clinical laboratory;
ii. The date a specimen was collected from
the individual;
iii. The type of
specimen collected;
iv. The type
of laboratory test performed; and
v. The laboratory test result and date of the
result; and
e. Whether
any of the following supported a diagnosis of neonatal abstinence syndrome:
i. A maternal history of opioid
use,
ii. A positive laboratory test
for opioid use by the individual's mother, or
iii. A positive laboratory test for opioids
in the individual;
5. If known, the following information about
the suspected neonatal abstinence syndrome:
a.
The source of the opioid believed to have caused the neonatal abstinence
syndrome; and
b. If the source of
the opioid used by the individual's mother was not through a prescription
order, as defined in A.R.S. §
32-1901,
the specific opioid used by the individual's mother; and
6. The date of the report.
E. A pharmacist who dispenses
naloxone or another opioid antagonist to an individual according to A.R.S. §
32-1979
shall, either personally or through a representative, submit a report as
required in A.R.S. §
32-1979
to document the dispensing.
F. A
medical examiner shall, either personally or through a representative, submit a
report to the Department, in a Department-provided format and within five
business days after the completion of the death investigation required in
A.R.S. §
11-594
on the human remains of a deceased individual with a suspected opioid overdose,
that includes:
1. The following information
about the medical examiner:
a. Name;
and
b. Street address, city,
county, and zip code;
2.
The following information about the deceased individual with a suspected opioid
overdose:
a. The deceased individual's
name;
b. The deceased individual's
date of birth;
c. The deceased
individual's gender;
d. The
deceased individual's race and ethnicity;
e. Whether the deceased individual was
pregnant and, if so, the expected date of delivery;
f. If applicable, the name of the deceased
individual's guardian; and
g.
Whether naloxone or another opioid antagonist was administered to the deceased
individual before the deceased individual's death and, if known:
i. The type of first response agency that
administered the naloxone or other opioid antagonist to the deceased
individual, or
ii. That the
naloxone or other opioid antagonist was administered to the deceased individual
by another individual;
3. The following information about the
diagnosis of opioid overdose:
a. The reason
for suspecting that the deceased individual had an opioid overdose;
b. The date of the opioid overdose;
c. The date of diagnosis; and
d. If the diagnosis was confirmed by clinical
laboratory tests:
i. The name, address, and
telephone number of the clinical laboratory;
ii. The date a specimen was collected from
the deceased individual;
iii. The
type of specimen collected;
iv. The
type of laboratory test performed; and
v. The laboratory test result and date of the
result;
4. If
applicable, a copy of the clinical laboratory test results;
5. If known, the following information about
the suspected opioid overdose:
a. Whether the
opioid overdose appeared to be intentional or unintentional;
b. The location where the opioid overdose
took place;
c. Whether the deceased
individual was alone at the time of the opioid overdose;
d. The specific opioid that appeared to be
responsible for the opioid overdose;
e. Whether the deceased individual was
prescribed an opioid within the 90 calendar days before the date of the opioid
overdose; and
f. Whether the opioid
overdose was the first time the deceased individual was known to have had an
opioid overdose and, if not, the number of previous opioid overdoses the
deceased individual had had;
6. Whether the deceased individual with the
suspected opioid overdose:
a. Died from the
suspected opioid overdose and, if so, the date of death; or
b. Died from another cause after experiencing
a suspected opioid overdose and, if so, the date of death; and
7. The date of the
report.
G. Information
collected on individuals pursuant to this Article is confidential according to:
1. A.R.S. §
36-133(F);
and
2. If applicable, A.R.S. §§
36-2401
through 36-2403.